Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Angela G Arnold"'
Autor:
Anastasia, Navitski, Duaa H, Al-Rawi, Vicky, Makker, Britta, Weigelt, Dmitriy, Zamarin, Ying, Liu, Angela G, Arnold, M Herman, Chui, Diana L, Mandelker, Michael, Walsh, Deborah F, DeLair, Karen A, Cadoo, Roisin E, O'Cearbhaill
Publikováno v:
JCO precision oncology. 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4167503b09e576bedb813726f11ddab8
https://pubmed.ncbi.nlm.nih.gov/36265117
https://pubmed.ncbi.nlm.nih.gov/36265117
Autor:
Sushmita Gordhandas, Eric Rios-Doria, Karen A Cadoo, Amanda Catchings, Anna Maio, Yelena Kemel, Margaret Sheehan, Megha Ranganathan, Dina Green, Anjali Aryamvally, Angela G Arnold, Erin Salo-Mullen, Beryl Manning-Geist, Tiffany Sia, Pier Selenica, Arnaud Da Cruz Paula, Chad Vanderbilt, Maksym Misyura, Mario M Leitao, Jennifer J Mueller, Vicky Makker, Maria Rubinstein, Claire F Friedman, Qin Zhou, Alexia Iasonos, Alicia Latham, Maria I Carlo, Yonina R Murciano-Goroff, Marie Will, Michael F Walsh, Shirin Issa Bhaloo, Lora H Ellenson, Ozge Ceyhan-Birsoy, Michael F Berger, Mark E Robson, Nadeem Abu-Rustum, Carol Aghajanian, Kenneth Offit, Zsofia Stadler, Britta Weigelt, Diana L Mandelker, Ying L Liu
Publikováno v:
JNCI: Journal of the National Cancer Institute. 115:560-569
Background We sought to determine the prevalence of germline pathogenic variants (gPVs) in unselected patients with endometrial cancer (EC), define biallelic gPVs within tumors, and describe their associations with clinicopathologic features. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec9f316b2b3f5be8abdd95005032897d
https://doi.org/10.1093/jnci/djad016
https://doi.org/10.1093/jnci/djad016
Autor:
Barry S. Taylor, Ingo K. Mellinghoff, Lisa M. DeAngelis, Marc Rosenblum, Cameron W. Brennan, Viviane S. Tabar, Timothy A. Chan, Philip H. Gutin, Alexandra M. Miller, Anna F. Piotrowski, Mariza Daras, Adrienne Boire, Christian Grommes, Jacqueline B. Stone, Eli L. Diamond, Thomas J. Kaley, Igor T. Gavrilovic, Antonio Omuro, Elena Pentsova, Craig P. Nolan, T. Jonathan Yang, Kathryn Beal, Allison Hyde, Malbora Manne, Andrew T. McKeown, Shweta S. Chavan, Shahiba Q. Ogilvie, Maryam Pourmaleki, Juliann Chmielecki, Michael E. Goldberg, Diana Mandelker, Zsofia K. Stadler, Angela G. Arnold, David B. Solit, Marc Ladanyi, Ahmet Zehir, Michael F. Berger, Bob T. Li, David M. Hyman, Natalie M. DiStefano, Robert J. Young, Andrew L. Lin, Philip Jonsson
Purpose:The genomic landscape of gliomas has been characterized and now contributes to disease classification, yet the relationship between molecular profile and disease progression and treatment response remain poorly understood.Experimental Design:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::641951579cd359e3e5caf9da91b7120d
https://doi.org/10.1158/1078-0432.c.6528149
https://doi.org/10.1158/1078-0432.c.6528149
Autor:
Barry S. Taylor, Ingo K. Mellinghoff, Lisa M. DeAngelis, Marc Rosenblum, Cameron W. Brennan, Viviane S. Tabar, Timothy A. Chan, Philip H. Gutin, Alexandra M. Miller, Anna F. Piotrowski, Mariza Daras, Adrienne Boire, Christian Grommes, Jacqueline B. Stone, Eli L. Diamond, Thomas J. Kaley, Igor T. Gavrilovic, Antonio Omuro, Elena Pentsova, Craig P. Nolan, T. Jonathan Yang, Kathryn Beal, Allison Hyde, Malbora Manne, Andrew T. McKeown, Shweta S. Chavan, Shahiba Q. Ogilvie, Maryam Pourmaleki, Juliann Chmielecki, Michael E. Goldberg, Diana Mandelker, Zsofia K. Stadler, Angela G. Arnold, David B. Solit, Marc Ladanyi, Ahmet Zehir, Michael F. Berger, Bob T. Li, David M. Hyman, Natalie M. DiStefano, Robert J. Young, Andrew L. Lin, Philip Jonsson
Table S1: Patient-level clinical annotation. Table S2: Sample-level clinical annotation. Table S3: Patient-level treatment lines. Table S4: Gene panels for targeted sequencing. Table S5: Somatic mutations. Table S6: Gene-level copy number alterations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ac7a093f2982213652b140852cf8ccb
https://doi.org/10.1158/1078-0432.22472180.v1
https://doi.org/10.1158/1078-0432.22472180.v1
Autor:
Barry S. Taylor, Ingo K. Mellinghoff, Lisa M. DeAngelis, Marc Rosenblum, Cameron W. Brennan, Viviane S. Tabar, Timothy A. Chan, Philip H. Gutin, Alexandra M. Miller, Anna F. Piotrowski, Mariza Daras, Adrienne Boire, Christian Grommes, Jacqueline B. Stone, Eli L. Diamond, Thomas J. Kaley, Igor T. Gavrilovic, Antonio Omuro, Elena Pentsova, Craig P. Nolan, T. Jonathan Yang, Kathryn Beal, Allison Hyde, Malbora Manne, Andrew T. McKeown, Shweta S. Chavan, Shahiba Q. Ogilvie, Maryam Pourmaleki, Juliann Chmielecki, Michael E. Goldberg, Diana Mandelker, Zsofia K. Stadler, Angela G. Arnold, David B. Solit, Marc Ladanyi, Ahmet Zehir, Michael F. Berger, Bob T. Li, David M. Hyman, Natalie M. DiStefano, Robert J. Young, Andrew L. Lin, Philip Jonsson
Figure S1: Distribution of systemic therapies received. Figure S2: Number of sequenced samples per patient. Figure S3: Subgroup-defining genomic lesions in IDH-wildtype and -mutant gliomas. Figure S4: Frequency of mutations in primary tumors. Figure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c4027dff8635107fa41557a7b76e27f
https://doi.org/10.1158/1078-0432.22472186
https://doi.org/10.1158/1078-0432.22472186
Autor:
Barry S. Taylor, Ingo K. Mellinghoff, Lisa M. DeAngelis, Marc Rosenblum, Cameron W. Brennan, Viviane S. Tabar, Timothy A. Chan, Philip H. Gutin, Alexandra M. Miller, Anna F. Piotrowski, Mariza Daras, Adrienne Boire, Christian Grommes, Jacqueline B. Stone, Eli L. Diamond, Thomas J. Kaley, Igor T. Gavrilovic, Antonio Omuro, Elena Pentsova, Craig P. Nolan, T. Jonathan Yang, Kathryn Beal, Allison Hyde, Malbora Manne, Andrew T. McKeown, Shweta S. Chavan, Shahiba Q. Ogilvie, Maryam Pourmaleki, Juliann Chmielecki, Michael E. Goldberg, Diana Mandelker, Zsofia K. Stadler, Angela G. Arnold, David B. Solit, Marc Ladanyi, Ahmet Zehir, Michael F. Berger, Bob T. Li, David M. Hyman, Natalie M. DiStefano, Robert J. Young, Andrew L. Lin, Philip Jonsson
List of Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89b012a1aef7c35ac455292434f5b79f
https://doi.org/10.1158/1078-0432.22472183.v1
https://doi.org/10.1158/1078-0432.22472183.v1
Autor:
David B. Solit, Angela G. Arnold, Mark E. Robson, Diana Mandelker, Michael F. Berger, Shweta S. Chavan, Maksym Misyura, Michael Walsh, Anna Maio, Sarah R. Kane, Karen Cadoo, Yelena Kemel, Preethi Srinivasan, Ying Liu, Jinru Shia, Kenneth Offit, Kelsey Breen, Jennifer Kennedy, Margaret Sheehan, Semanti Mukherjee, Caitlin Bourque, Chaitanya Bandlamudi, Zalak Patel, Maria I. Carlo, Zsofia K. Stadler, Amanda Catchings, Erin E. Salo-Mullen, Arnold J. Markowitz, Barry S. Taylor, Prince Rainier Tejada, Rosalba Sacca, Vanessa Marcell, Alicia Latham, Ozge Ceyhan-Birsoy, Mark T.A. Donoghue, Kimberly Amoroso, Megha Ranganathan
Publikováno v:
JCO Precision Oncology. :455-465
PURPOSE NTHL1 and MSH3 have been implicated as autosomal recessive cancer predisposition genes. Although individuals with biallelic NTHL1 and MSH3 pathogenic variants (PVs) have increased cancer and polyposis risk, risks for monoallelic carriers are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ba859253338af25f8aa87589967d494
https://doi.org/10.1200/po.20.00443
https://doi.org/10.1200/po.20.00443
Autor:
Anastasia Navitski, Duaa H. Al-Rawi, Vicky Makker, Britta Weigelt, Dmitriy Zamarin, Ying Liu, Angela G. Arnold, M. Herman Chui, Diana L. Mandelker, Michael Walsh, Deborah F. DeLair, Karen A. Cadoo, Roisin E. O'Cearbhaill
Publikováno v:
JCO Precision Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6463a4fdb484202ad7a69e92990dbea
https://doi.org/10.1200/po.22.00349
https://doi.org/10.1200/po.22.00349
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Mutations in RAD51D are associated with a predisposition to primary ovarian, fallopian tube, and peritoneal carcinoma. Beyond ovarian cancer, recent studies have also suggested that mutations in RAD51D could confer increased risk of triple n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f37cae73291099d2ddc7e3725f5d0e8
https://doi.org/10.1007/s10549-020-06066-7
https://doi.org/10.1007/s10549-020-06066-7
Autor:
Ying L. Liu, Anna Maio, Yelena Kemel, Erin E. Salo‐Mullen, Margaret Sheehan, Prince Ray Tejada, Magan Trottier, Angela G. Arnold, Megan Harlan Fleischut, Alicia Latham, Maria I. Carlo, Yonina R. Murciano‐Goroff, Michael F. Walsh, Diana Mandelker, Nikita Mehta, Chaitanya Bandlamudi, Kanika Arora, Ahmet Zehir, Michael F. Berger, David B. Solit, Carol Aghajanian, Luis A. Diaz, Mark E. Robson, Carol L. Brown, Kenneth Offit, Jada G. Hamilton, Zsofia K. Stadler
Publikováno v:
CancerREFERENCES. 128(21)
Germline risk assessment is increasing as part of cancer care; however, disparities in subsequent genetic counseling are unknown.Pan-cancer patients were prospectively consented to tumor-normal sequencing via custom next generation sequencing panel (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ffb1325acf2187b07cabf51a21770cb
https://pubmed.ncbi.nlm.nih.gov/36041233
https://pubmed.ncbi.nlm.nih.gov/36041233